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associated with lower peak V O 2 , and these associations were 
independent of age, gender, medication, FEV 1 and oxygen-
ation. The relationship between MR-proANP, MR-proADM, 
and CT-proET-1 and peak V O 2 was significant whether pa-
tients had an obstructive ventilatory disease or not.  Conclu-
sions: In patients with chronic lung disease, several biomark-
ers known to reflect measures of cardiac function were
associated with peak V O 2 independent of lung function,
indicating that cardiac strain may contribute to exercise lim-
itation in these patients due to concomitant cardiac disease 
or in the context of a pulmonary-cardiac interaction. 
 Copyright © 2010 S. Karger AG, Basel 
 Introduction 
 Cardiopulmonary exercise testing (CPET) is an estab-
lished tool for risk stratification in patients with a variety 
of pulmonary diseases including chronic obstructive pul-
monary disease (COPD), interstitial lung disease, pulmo-
nary vascular disorders, and cystic fibrosis  [1–3] . The 
prognostic power of peak oxygen uptake (peak V O 2 ) in 
these patients is explained by the fact that peak V O 2 is not 
only a measure of the degree of impairment of ventilation 
and gas exchange but also reflects nonpulmonary com-
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 Abstract 
 Background: Peak oxygen uptake (peak V O 2 ) is a predictor 
of outcome in patients with lung disease. In these patients, 
peak V O 2 is typically determined by ventilation and gas ex-
change. However, it is not well known whether cardiac strain 
contributes to peak V O 2 in patients with chronic lung disease. 
 Objective: To assess the relationship between several novel 
biomarkers reflecting different aspects of cardiac function 
and peak V O 2 in patients with chronic lung disease.  Methods: 
Plasma concentrations of midregional pro-A-type natriuret-
ic peptide (MR-proANP), midregional proadrenomedullin 
(MR-proADM), C-terminal proendothelin-1 (CT-proET-1), and 
C-terminal provasopressin (copeptin) were measured in 85 
patients with a variety of chronic pulmonary diseases [age 
57  8 14 years, forced expiratory volume in the 1st second 
(FEV 1 ) 76  8 23% of the predicted value] undergoing maxi-
mal cardiopulmonary exercise testing (peak V O 2 18.6  8 6.6 
ml/kg/min).  Results: Raised MR-proANP (r = –0.54), MR-
proADM (r = –0.54), and CT-proET-1 (r = –0.49; p  ! 0.001 for 
all) but not copeptin (r = –0.05; p = 0.68) concentrations were 
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ponents of exercise capacity, such as cardiac output and 
muscular adaptation to exercise, and thereby represents 
an integrative measurement of response to exercise. How-
ever, the contribution of cardiovascular factors to exer-
cise limitation in patients with lung disease is not well 
documented. We have previously shown that in patients 
with chronic lung disease, B-type natriuretic peptide and 
 N -terminal-pro-B-type natriuretic peptide (NT-proBNP) 
were independent predictors of a peak V O 2  ! 15 ml/kg/
min  [4] , which is an established cut-off indicating an in-
creased risk of perioperative complications in patients 
with lung disease being considered for lung cancer sur-
gery who cannot be considered as low risk based on their 
forced expiratory volume in the 1st second (FEV 1 ) and 
diffusion capacity  [2, 5–7] . This seems to indicate that 
cardiac strain may significantly contribute to peak V O 2 in 
patients with lung disease. In fact, recent studies suggest-
ed a close link between pulmonary and cardiac function 
in patients with lung disease  [8, 9] .
 In patients with cardiac disease, several novel bio-
markers, such as midregional pro-A-type natriuretic pep-
tide (MR-proANP)  [10–12] , midregional proadreno-
medullin (MR-proADM)  [13] , C-terminal proendothe-
lin-1 (CT-proET-1)  [14] , and C-terminal provasopressin 
(CT-proAVP, copeptin)  [15, 16] , which are promising 
markers of pathophysiological processes, have been 
shown to be as accurate or even more accurate in predict-
ing prognosis than the established B-type natriuretic 
peptides. MR-proANP is the stable midregional part of 
the ANP precursor peptide and is thereby considered to 
be a marker of left atrial stretch  [17] . In patients with 
chronic heart failure (HF), MR-proANP is a marker of 
left-ventricular ejection fraction (LVEF) and mortality 
 [11, 12] , and in postmyocardial infarction (MI) patients, 
MR-proANP is a marker of outcome too  [10] . MR-pro-
ADM is the midregional part of the precursor peptide of 
adrenomedullin, a peptide with vasorelaxing and natri-
uretic properties  [18] . In HF patients, adrenomedullin is 
released from the myocardium  [18] and is a prognostic 
marker  [19] . CT-proET-1 is the C-terminal part of the 
precursor peptide of endothelin-1 (ET-1), an endotheli-
um-derived vasoconstrictor contributing to heightened 
systemic  [20] and pulmonary vascular tone  [21] . CT-pro-
ET-1 is a prognostic marker in the post-MI setting  [14] . 
Copeptin is the C-terminal fragment of the AVP precur-
sor peptide and thereby reflects plasma osmolality but 
interestingly seems also to be a marker of the individual 
stress level  [22] . Copeptin has been shown to be an early 
marker of acute MI and a marker of left-ventricular
remodeling and dysfunction in the post-MI setting  [23] . 
In addition, copeptin provides prognostic information in 
patients post-MI  [23] and those with chronic HF  [15] . The 
advantage of these four novel markers over measurement 
of the biologically active substances lies in the fact that 
prohormones have a longer half-life and thereby repre-
sent more reliable analytes.
 Accordingly, the aim of the present study was to assess 
the relationship between MR-proANP, MR-proADM, 
CT-proET-1, and copeptin and peak V O 2 in patients with 
chronic lung disease. We hypothesized that raised con-
centrations of these markers were associated with lower 
peak V O 2 .
 Methods 
 Study Design 
 One-hundred and four consecutive patients with chronic lung 
disease referred for CPET for the evaluation of exercise capacity 
were eligible. There were no a priori exclusion criteria. Nineteen 
patients not fulfilling criteria for appropriate effort (see below) 
were secondarily excluded, leaving 85 patients for the present 
analysis. The study population represents a subgroup of a popula-
tion on which we have reported previously  [24] . All patients un-
derwent CPET including spirometry and blood gases as well as 
biomarker measurement in a prospective manner. Information 
on cardiac function was obtained from previously performed 
echocardiograms. The study was approved by the Ethics Com-
mittee of Basel. Written informed consent was obtained from all 
participating patients.
 CPET Procedures 
 Spirometry for measurement of FEV 1 and forced vital capacity 
(FVC) was performed immediately before CPET. Thereafter, pa-
tients underwent symptom-limited upright cycle exercise tests 
(Jaeger, Würzburg, Germany) using ramp protocols with contin-
uous monitoring of the electrocardiogram and noninvasive blood 
pressure measurement every second minute. Standard criteria for 
test termination were applied  [25] . Minute ventilation (VE), V O 2 , 
and carbon dioxide output (V CO 2 ) were obtained breath by breath 
and averaged at 30-second intervals (SensorMedics Yorba Linda, 
Calif., USA). Peak V O 2 was expressed as the highest 10-second 
average values obtained during the last 30 s of the test. Peak V O 2 
was expressed as body weight-indexed data as well as %predicted 
peak V O 2 . Oxygen pulse was calculated as peak V O 2 divided by 
peak heart rate. Ventilatory efficiency was expressed as the peak 
VE/V CO 2 ratio, which, similarly to the VE/V CO 2 slope, is a strong 
predictor of outcome in patients with HF  [26] . Arterial blood was 
obtained at rest and peak exercise (i.e. immediately after cessation 
of exercise) from a radial or brachial artery and analyzed imme-
diately. Maximal or near-maximal effort was assumed if at least 
one of the following criteria was fulfilled: (1) peak heart rate  1 80% 
predicted; (2) respiratory exchange ratio  1 1.2; (3) lactate at peak 
exercise (measured in arterial blood with a blood gas analyzer) 
 1 4.0 mmol/l, or (4) difference between base excess at rest and 
peak exercise  ^  2.5 mmol/l  [27] .
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 Biomarker Measurement 
 A specimen of venous blood was drawn from an antecubital 
vein immediately before the test in the seated position. Samples 
were collected in plastic tubes containing ethylenediaminetetraac-
etatic acid (EDTA), placed on ice, centrifuged at 3,000  g, and stored 
at –80  °  C. Plasma samples were analyzed approximately 1 year after 
collection by laboratory technicians blinded to patient characteris-
tics and CPET results. Biomarkers were measured using novel as-
says which have been described in detail elsewhere  [28–31] . MR-
proANP was measured using the BRAHMS MR-proANP LIA  [28] , 
MR-proADM was measured using the BRAHMS MR-proADM 
LIA  [29] , CT-proET-1 was measured using the BRAHMS CT-pro-
ET-1 LIA  [30] , and copeptin was measured using the BRAHMS 
CT-proAVP LIA  [31] (all assays from BRAHMS AG, Hennigsdorf, 
Germany). The stability at –20  °  C during 6 months has been dem-
onstrated for MR-proANP  [28] , MR-proADM  [29] , and CT-pro-
ET-1  [30] . Similar data demonstrating the stability of copeptin dur-
ing long-term storage are not available. However, the excellent sta-
bility of copeptin in EDTA plasma at room temperature has been 
demonstrated previously. After 14 days at room temperature in 
EDTA plasma, the mean measured value was still 97.6% of the ini-
tial value measured in EDTA plasma. After 4 cycles of freezing and 
thawing the mean measured value was 102% of the original value 
 [31] . Based on these data, we think that it can be extrapolated that 
long-term storage at –80  °  C is a suitable storage method.
 Statistical Analysis 
 Data were expressed as counts and percentages, means  8 
standard deviation (SD), and median (interquartile range). We 
compared patients with an FEV 1 /FVC ratio  ! 0.70 as measured 
under therapy on the day of the test (i.e. patients with irreversible 
obstruction) and patients with an FEV 1 /FVC ratio  1 0.70 using the 
  2 test, unpaired t test, or Mann-Whitney U test. The rationale for 
this approach is based on the observation that the degree of air-
flow obstruction is related to cardiac output  [8] , and that we want-
ed to assess whether our results apply for patients with obstructive 
and nonobstructive pathology. Correlations between parameters 
of interest were performed using Spearman correlation coeffi-
cients. Multivariable linear regression with body weight-indexed 
peak V O 2 and %predicted V O 2 as dependent variables was per-
formed with all available information and measurements at rest 
( tables 1 ,  2 ) as covariates (ln-transformation in case of a skewed 
distribution). We performed direct as well as backward and for-
ward models for each of the four biomarkers. In addition, an anal-
ysis with peak V O 2 as a categorical variable was performed using 
the previously published cut-off of 15 ml/kg/min  [5–7] . Receiver 
operator characteristics (ROC) curves were constructed to illus-
trate the ability of the biomarkers to reflect a peak V O 2  ! 15 ml/
kg/min. Areas under the ROC curves (AUC) were compared us-
ing the method of DeLong et al.  [32] . Multivariable logistic regres-
sion was then performed to identify independent predictors of a 
Table 1.  Baseline characteristics of the entire study population and of patients with an FEV1/FVC ratio <0.7 
versus 60.7
All
(n = 85)
FEV1/FVC
<0.7 (n = 40)
FEV1/FVC
≥0.7 (n = 45)
p value
Age, years 57814 59814 55815 0.17
Male gender 50 (59%) 18 (45%) 32 (71%) 0.02
Body mass index, kg/m2 26.084.7 25.484.5 26.684.9 0.24
COPD 39 (46%) 26 (65%) 13 (29%) 0.001
Bronchial asthma 13 (15%) 5 (13%) 8 (18%) 0.50
Other lung disease1 33 (39%) 9 (23%) 24 (53%) 0.004
Lung cancer 33 (39%) 21 (53%) 12 (27%) 0.02
Other medical history
Coronary artery disease 15 (18%) 8 (20%) 7 (16%) 0.59
Previous myocardial infarction 10 (12%) 6 (15%) 4 (9%) 0.38
Other heart disease 8 (9%) 3 (8%) 5 (11%) 0.65
Diabetes mellitus 7 (8%) 3 (8%) 4 (9%) 0.82
Current smoking 25 (29%) 16 (40%) 9 (20%) 0.04
Previous smoking 40 (47%) 15 (38%) 25 (56%) 0.10
Medication
Inhaled corticosteroids 28 (33%) 18 (45%) 10 (22%) 0.03
Inhaled 2-mimetics 33 (39%) 21 (53%) 12 (27%) 0.02
-Blockers 16 (19%) 6 (15%) 10 (22%) 0.40
ACEI/ARB 15 (18%) 9 (23%) 6 (13%) 0.27
Diuretic 13 (15%) 4 (10%) 9 (20%) 0.01
Aspirin 15 (18%) 7 (18%) 8 (18%) 0.97
Statin 19 (22%) 8 (20%) 11 (24%) 0.62
Data are given as numbers and percentages or means 8 SD.  ACEI/ARB = Angiotensin-converting enzyme 
inhibitor or angiotensin receptor blocker. 1 For details, see text.
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peak V O 2  ! 15 ml/kg/min. All parameters available before the ex-
ercise test ( tables 1 ,  2 ; first model) as well as biomarkers (addi-
tional models) were tested. p  ! 0.05 was considered statistically 
significant. Analysis was performed using commercially available 
software packages (SPSS/PC, version 15.0, SPSS Inc., Chicago, Ill., 
USA, and Analyse-it V2.04, Leeds, UK).
 Results 
 Patient Characteristics 
 We studied 85 patients with the following primary di-
agnoses: 39 (46%) had COPD, 13 (15%) had asthma and 
33 (39%) had other lung diseases, including sarcoidosis
(n = 3), pulmonary arterial hypertension (n = 2), intersti-
tial lung disease (n = 6), alveolitis (n = 1), bronchiectasis
(n = 2), unclear lung diseases (n = 2), or lung cancer/me-
sothelioma (n = 17). Fifteen patients also had lung cancer 
along with another pulmonary disease. The characteris-
tics of the entire study group are presented in  table 1 .
 Measurements at Rest and Responses to Exercise 
 Measurements at rest and responses to exercise are 
shown in  tables 2 and  3 . As expected, we studied a popu-
lation with overall clearly abnormal lung function and 
impaired functional capacity as indicated by a mean 
%predicted peak V O 2 of 71%. Forty (47%) patients had an 
obstructive ventilator defect on the day of CPET.
 Biomarker Concentrations 
 The median MR-proANP, MR-proADM, CT-proET-1, 
and copeptin concentrations and interquartile ranges are 
presented in  table 4 . As shown in  table 5 , there were sig-
nificant correlations between the biomarkers, with r 2 val-
ues ranging from to 0.06 to 0.48.
 Relationship between Biomarkers and Peak V O 2 
 There were moderate inverse correlations between 
peak V O 2 and MR-proANP, MR-proADM and CT-
proET-1 (p  ! 0.001 for all) but not copeptin ( fig. 1 ). In all 
multivariable linear regression models, lower MR-pro-
ANP (  = –0.32; p  ! 0.001) was an independent predictor 
of a higher peak V O 2 . Higher FEV 1 , higher arterial oxygen 
pressure (Pa O 2 ), higher arterial carbon dioxide pressure 
(Pa CO 2 ), and lower body mass index (BMI) were addi-
tional independent predictors of higher peak V O 2 . In 
some models (forward models), lower MR-proADM (  = 
–0.32; p  ! 0.001) along with higher FEV 1 , higher Pa O 2 , 
higher Pa CO 2 , and lower BMI, and lower CT-proET-1
(  = –0.29; p = 0.001) along with higher FEV 1 , higher 
Table 2.  Measurements at rest in the entire study population and in patients with an FEV1/FVC  ratio <0.7 ver-
sus 60.7
All
(n = 85)
FEV1/FVC
<0.7 (n = 40)
FEV1/FVC
≥0.7 (n = 45)
p value
Heart rate, bpm 83815 83816 83814 0.72
Systolic blood pressure, mm Hg 127819 127817 127820 0.98
Diastolic blood pressure, mm Hg 86812 82813 89810 0.02
Creatinine clearance, ml/min 94833 93834 96832 0.70
LVEF, % 60 (55–65) n = 40 60 (52–65) n = 18 60 (60–65) n = 22 0.18
Respiratory rate, min–1 1986 2086 1986 0.42
FVC, l 3.2281.00 2.9580.96 3.4680.98 0.02
%predicted FVC, % 92820 92819 92822 0.96
FEV1, l 2.1980.84 1.7080.64 2.6280.77 <0.001
%predicted FEV1, % 76823 65818 85822 <0.001
FEV1/FVC 0.6780.12 0.5880.09 0.7680.07 <0.001
Hemoglobin, g/dl 14.282.0 13.681.9 14.681.9 0.01
PaO2, mm Hg 80813 75811 84814 0.003
SaO2, % 95 (93–96) 94 (91–96) 95 (93–96) 0.03
PaCO2, mm Hg 3585 3684 3485 0.16
D(A – a)O2, mm Hg 25814 30813 21813 0.006
D ata are given as means 8 SD or medians (interquartile range in parentheses). SaO2 = Arterial oxygen satu-
ration; D(A – a)O2 = alveolo-arterial oxygen pressure difference.
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Table 3.  Measurements at peak exercise in the entire study population and in patients with an FEV1/FVC ratio 
<0.7 versus 60.7
All
(n = 85)
FEV1/FVC
<0.7 (n = 40)
FEV1/FVC
≥0.7 (n = 45)
p value
Duration of exercise, min 6.0 (4.8–7.0) 5.0 (4.2–6.0) 6.6 (5.7–8.0) <0.001
Peak heart rate, bpm 139825 137824 140826 0.48
Predicted heart rate, % 85814 84813 85814 0.93
Systolic blood pressure, mm Hg 183831 188833 179829 0.20
Diastolic blood pressure, mm Hg 92816 92818 92814 0.96
Respiratory rate, min–1 3588 3387 3789 0.04
Peak work rate, W/kg 1.6280.65 1.4780.54 1.7680.71 0.04
Peak VO2, l/min 1.3880.58 1.2480.57 1.5080.57 0.04
Peak VO2, ml/kg/min 18.686.6 17.586.2 19.686.9 0.14
Predicted peak VO2, % 71819 71817 70821 0.86
 VO2/ work rate, ml/W/min 9.481.9 9.481.5 9.382.1 0.69
Peak oxygen pulse, ml/beat 9.883.4 8.983.2 10.783.4 0.01
Respiratory exchange ratio 1.1880.14 1.1580.14 1.2080.14 0.08
VE, l/min 60823 51819 69823 <0.001
Peak VE/VCO2 39.089.9 37.988.4 39.9811.1 0.35
PaO2, mm Hg 86821 80820 92822 0.008
SaO2, % 95 (91–96) 93 (90–95) 95 (93–96) 0.07
PaCO2, mm Hg 3586 3885 3385 0.001
D(A – a)O2, mm Hg 29819 32817 26821 0.18
pH 7.36 (7.33–7.39) 7.37 (7.33–7.39) 7.36 (7.32–7.40) 0.90
Lactate, mmol/l 5.8 (4.4–7.7) 5.8 (4.2–7.1) 5.9 (4.4–8.5) 0.25
D ata are given as means 8 SD or medians (interquartile range in parentheses). SaO2 = Arterial oxygen satu-
ration; D(A – a)O2 = alveolo-arterial oxygen pressure difference.
Table 4.  Biomarkers in the entire study population and of patients with an FEV1/FVC  ratio <0.7 versus 60.7
All
(n = 85)
FEV1/FVC <0.7
(n = 40)
FEV1/FVC ≥0.7
(n = 45)
p value
MR-proANP, pmol/l 62.5 (40.0–97.7) 72.9 (43.3–112.5) 57.7 (37.0–84.0) 0.10
MR-proADM, nmol/l 0.57 (0.46–0.76) 0.62 (0.46–0.78) 0.54 (0.47–0.75) 0.38
CT-proET-1, pmol/l 68.0 (53.6–88.2) 66.1 (54.2–88.5) 68.9 (52.6–88.2) 0.96
CT-proAVP, pmol/l 6.5 (4.8–10.2) 5.78 (4.17–8.31) 7.49 (5.11–12.0) 0.03
D ata are given as medians (interquartile range in parentheses). 
Table 5.  Correlations between biomarkers
MR-proANP MR-proADM CT-proET-1 CT-proAVP
MR-proANP – r = 0.69; p < 0.001 r = 0.55; p < 0.001 r = 0.25; p = 0.02
MR-proADM r = 0.69; p < 0.001 – r = 0.72; p < 0.001 r = 0.43; p < 0.001
CT-proET-1 r = 0.55; p < 0.001 r = 0.72; p < 0.001 – r = 0.26; p = 0.02
CT-proAVP r = 0.25; p = 0.02 r = 0.43; p < 0.001 r = 0.26; p = 0.02 –
S pearman correlation coefficients are given. 
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Pa O 2 , and lower BMI were also independently associated 
with higher peak V O 2 .
 If peak V O 2 was expressed as %predicted value, it was 
significantly and inversely related to MR-proADM (r = 
–0.25; p = 0.02) and CT-proET-1 (r = –0.27; p = 0.01) but 
not MR-proANP (r = –0.19; p = 0.09) and copeptin (r = 
–0.13; p = 0.22). After multivariable adjustment, the as-
sociations between MR-proADM and CT-proET-1 and 
%predicted peak V O 2 were no longer significant, however 
(data no shown).
 Biomarkers for the Prediction of a Peak
V O 2  ! 15 ml/min/kg 
 When using peak V O 2 as a categorical variable, MR-
proANP [105.0 (52.5–164.0) vs. 50.4 (36.9–79.4) pmol/l], 
MR-proADM [0.74 (0.56–0.95) vs. 0.54 (0.41–0.71) 
nmol/l], CT-proET-1 [86.6 (74.4–104.9) vs. 59.4 (52.1–
75.5) pmol/l] (p  ! 0.001 for all) but not copeptin [7.5 (5.6–
10.3) vs. 6.0 (4.4–10.1) pmol/l; p = 0.21] concentrations 
were significantly raised in patients with peak V O 2  ! 15 
ml/kg/min as compared to those with peak V O 2  6 15 ml/
kg/min. As shown in  figure 2 , the AUC for MR-proANP, 
0
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 Fig. 1. Scatter plots showing the correlations between MR-proANP ( a ), MR-proADM ( b ), CT-proET-1 ( c ) and 
CT-proAVP ( d ) and peak V O 2 . Spearman correlation coefficients are given. Note the logarithmic scale for MR-
proANP. 
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MR-proADM, and CT-proET-1 for the prediction of a 
peak V O 2  ! 15 ml/kg/min were 0.74, 0.74, and 0.78 (p  1 0.4 
for all comparisons between the AUC).
 Multivariable logistic regression (separate models for 
each marker) revealed higher MR-proANP, higher MR-
proADM, and higher CT-proET-1 as independent predic-
tors of a peak V O 2  ! 15 ml/kg/min. Other independent 
predictors of a peak V O 2  ! 15 ml/kg/min included lower 
FEV 1 , the presence of diabetes, and aspirin use (data not 
shown). In a model with all three biomarkers, only CT-
proET-1 remained independently predictive of peak V O 2 
 ! 15 ml/kg/min.
 Relationship between Biomarkers and Oxygen Pulse 
and Ventilatory Efficiency 
 There were significant inverse correlations between 
MR-proANP (r = –0.31; p = 0.004), MR-proADM (r = 
–0.23; p = 0.03), and CT-proET-1 (r = –0.30; p = 0.005) 
and peak exercise oxygen pulse. In contrast, there was a 
trend towards a direct association between copeptin and 
oxygen pulse (r = 0.21; p = 0.06). In addition, there were 
direct correlations between MR-proANP (r = 0.32; p = 
0.003), MR-proADM (r = 0.29; p = 0.007), and CT-
proET-1 (r = 0.30; p = 0.005) but not copeptin (r = 0.09;
p = 0.4) and the peak exercise VE/V CO 2 ratio.
 Comparison of Patients with FEV 1 /FVC  ! 0.7 versus 
 6 0.7 
 As shown in  tables 1–3 , patients with FEV 1 /FVC  ! 0.7 
(n = 40) and those with FEV 1 /FVC  6 0.7 (n = 45) differed 
considerably with respect to gender, history, medication, 
lung function and blood gases at rest, and exercise re-
sponses. However, %predicted peak V O 2 was very similar 
between groups. Whilst there were no significant differ-
ences in MR-proANP, MR-proADM, and CT-proET-1 be-
tween the groups, copeptin was significantly lower in pa-
tients with FEV 1 /FVC  ! 0.7 compared to those with FEV 1 /
FVC  6 0.7 ( table  4 ). The inverse relationship between 
raised MR-proANP (FEV 1 /FVC  ! 0.7: r = –0.42; FEV 1 /
FVC  6 0.7: r = –0.38), MR-proADM (r = –0.52; r = –0.51), 
and CT-proET-1 (r = –0.42; r = –0.42) with peak V O 2 was 
present in both patients with FEV 1 /FVC  ! 0.7 and those 
with FEV 1 /FVC  6 0.7 (p  ! 0.05 for all correlations).
 Subgroup Analyses 
 In patients with available information on LVEF (n = 
40), we observed similar inverse correlations between 
MR-proANP (r = –0.52; p = 0.001), MR-proADM (r = 
–0.46; p = 0.003), and CT-proET-1 (r = –0.53; p  ! 0.001) 
and peak V O 2 as in the study population as a whole. There 
was also a significant but weaker correlation between 
LVEF and peak V O 2 (r = 0.32; p = 0.047) whereas there 
was no significant correlation between LVEF and bio-
markers (data not shown). All correlations between the 
three biomarkers and peak V O 2 remained statistically sig-
nificant after adjustment for LVEF.
 If the analysis was restricted to patients with BMI  ! 30 
kg/m 2 (n = 69), MR-proANP (r = –0.52), MR-proADM
(r = –0.53), and CT-proET-1 (r = –0.50; p  ! 0.001 for all) 
but not copeptin (r = 0.04; p = 0.8) were inversely associ-
ated with peak V O 2 . In those with BMI  6 30 kg/m 2 (n = 
16), these correlations were even stronger (MR-proANP: 
r = –0.74, MR-proADM: r = –0.61, CT-proET-1: r = –0.62; 
p  ! 0.05 for all).
 Discussion 
 The present study evaluating the association between 
biomarkers previously assessed in patients with cardio-
vascular disease and peak V O 2 in patients with chronic 
lung disease revealed that raised MR-proANP, MR-
proADM, and CT-proET-1 were associated with lower 
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 Fig. 2. ROC curves showing the accuracy of MR-proANP, MR-
proADM and CT-proET-1 in predicting a peak V O 2  ! 15 ml/kg/
min. AUC and 95% confidence intervals are given. 
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peak V O 2 independent of lung function, blood gases and 
medication.
 Given that MR-proANP, MR-proADM and CT-
proET-1 provided information on peak V O 2 independent 
of FEV 1 , they may reflect the cardiac output factor in 
peak V O 2 equation. Similarly to NT-proBNP  [33, 34] , 
these biomarkers may be surrogates for coexisting left-
sided cardiac dysfunction and thus exercise-induced 
postcapillary pulmonary hypertension. In fact, we found 
a weak inverse correlation between MR-proANP, MR-
proADM and CT-proET-1, and peak exercise oxygen 
pulse, potentially indicating a relationship with left-ven-
tricular stroke volume during exercise, although this re-
mains speculative given that oxygen pulse is not only de-
termined by stroke volume but also the arteriovenous 
oxygen extraction, which we did not measure. In HF pa-
tients, an association between ET-1 and peak V O 2 has 
been described previously  [35] . In the subgroup with 
available data on LVEF, MR-proANP, MR-proADM and 
CT-proET-1 were significantly and inversely related to 
peak V O 2 after adjustment for LVEF, suggesting that these 
markers may provide composite information on cardio-
vascular strain beyond LVEF.
 In addition, there seems to be an interaction between 
pulmonary and cardiac function  [9, 36] , per se associat-
ed with an impaired exercise capacity  [9] . Patients with 
COPD and hyperinflation have been shown to have a 
lower peak V O 2 and lower oxygen pulse than patients 
without hyperinflation  [9] , potentially suggesting a lower 
stroke volume in those with hyperinflation  [9] . Possible 
mechanisms leading to a decreased left-ventricular stroke 
volume and thus peak V O 2 in patients with both COPD 
and other lung diseases include exercise-induced precap-
illary pulmonary hypertension due to decreased pulmo-
nary vascular bed and increased vasoreactivity  [37] , left-
ventricular diastolic dysfunction due to left-to-right ven-
tricular interaction in the presence of pulmonary hy-
pertension  [38] as well as decreased venous return due to 
increased intrathoracic pressures  [36] . Again, these spec-
ulations are limited by the fact that the value of oxygen 
pulse as a measure of stroke volume in patients with lung 
disease remains unclear  [3] . However, in a recent popula-
tion-based study, a greater extent of emphysema and 
more severe airflow obstruction were linearly related to 
impaired left-ventricular filling and lower stroke volume 
as assessed by cardiac magnetic resonance imaging  [8] . 
Thus, although the underlying mechanisms are not fully 
understood, COPD and most likely also other lung dis-
eases seem, per se, to be associated with some sort of car-
diac exercise limitation.
 The rationale for the use of these biomarkers was two-
fold: first, each of the novel biomarkers quantifies a dis-
tinct and important pathophysiological process or regu-
latory mechanism known to be of prognostic value in 
various diseases including HF. Second, these biomarkers 
have excellent preanalytical and analytical properties as 
they are inactive and stable fragments of precursor pep-
tides of and thus surrogates for key hormones, which are 
upregulated in HF and either promote adverse effects by 
fluid retention and vasoconstriction or, similarly to B-
type natriuretic peptide, reflect an insufficient counter-
regulatory release of hormones with natriuretic and va-
sodilator properties  [39] . Biomarker concentrations were 
measured from stored samples, and the stability at –80° 
during one 1 year has not formally been shown for all of 
these peptides. However, available data suggest excellent 
stability during 6–12 months for MR-proANP, MR-
proADM, and CT-proET-1. Data on the stability of co-
peptin during long-term storage are not available. We ac-
knowledge that despite excellent stability at room tem-
perature during 2 weeks  [31] , some uncertainty persists.
 Only approximately 24–29% of the variability of body 
weight-indexed peak V O 2 was explained by biomarkers, 
clearly indicating that the isolated use of these biomark-
ers is not accurate enough to predict peak V O 2 . However, 
the purpose of this study was not to propose replacement 
of CPET by biomarkers but to characterize their associa-
tions with pathophysiology. We demonstrated that bio-
markers provide information on the response to exercise 
beyond the set of tests typically included in the armamen-
tarium of the respiratory physician, i.e. measures of lung 
function. We used different statistical approaches and 
performed subgroup analyses, and this observation was 
consistent. The inverse association between peak V O 2 and 
biomarker concentrations was similar in patients with an 
obstructive and non-obstructive pathology, indicating 
that these markers may be of value in a large spectrum of 
lung disease. Given the relative paucity of simple bio-
markers in the prognostic assessment of patients with 
chronic lung disease, our result may be the basis for fu-
ture studies on the prognostic value of MR-proANP, MR-
proADM and CT-proET-1 in this setting.
 We did not perform a detailed echocardiographic 
evaluation, which is a limitation of our study. Thus, the 
link between biomarkers and the exercise response re-
mains speculative. It is, however, possible that similarly 
to NT-proBNP  [33] , raised MR-proANP, MR-proADM, 
and CT-proET-1 concentrations identify patients requir-
ing an echocardiogram not only to look for LVEF but also 
for left-ventricular diastolic dysfunction and valvular 
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heart disease. It is also possible that raised biomarkers 
reflect the severity of the pulmonary-cardiac interaction 
as discussed above which is, however, difficult to quan-
tify. Noninvasive measurement of pulmonary pressures 
by echocardiography at rest is problematic because on the 
one hand it is technically challenging in patients with ad-
vanced lung disease  [40] , and on the other hand it does 
not predict the exercise response.
 According to the Fick equation, peak V O 2 and oxygen 
pulse are not only determined by cardiac output and 
stroke volume, respectively, but also by peripheral oxygen 
extraction. We acknowledge that we did not assess the 
physical activity level and skeletal muscle mass and mor-
phology (‘the periphery’), which is another limitation of 
the study. Muscle atrophy and dysfunction is a common 
feature in patients with advanced COPD and has signifi-
cant impact on exercise tolerance  [41] . It remains un-
known whether the biomarkers in our study are related 
to measures of muscle mass und function. In hemodialy-
sis patients, MR-proADM and C-reactive protein have 
both been shown to be related to measures of cardiac 
function and thus to systemic inflammation  [42] . It is 
possible that via a link with systemic inflammation mus-
cle wasting has also contributed to the association be-
tween the biomarkers evaluated in this study and peak 
V O 2 . A relationship between raised C-reactive protein 
and raised NT-proBNP in patients with lung disease has 
been shown previously  [43] . Our study has a number of 
limitations as discussed above. In addition, we studied a 
small and heterogeneous population. Differences in lev-
els of inflammatory cytokines in this patient group might 
have had an effect on muscular contractile function and 
mitochondrial potential. However, we have tried to show 
that our findings apply for patients with different pulmo-
nary pathophysiology. Second, this is a cross-sectional 
study design, which fails to provide a causal relation be-
tween factors.
 Conclusions 
 In patients with lung disease, MR-proANP, MR-
proADM, and CT-proET-1 are inversely associated with 
peak V O 2 , and this occurs independent of lung function 
and oxygenation. These results may be the basis for future 
studies on the nature of the link between peak V O 2 and 
these markers and their prognostic value in patients with 
chronic lung disease.
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